Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca

2022-12-26

疫苗

SOKA, Japan--(BUSINESS WIRE)-- Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in "Innovation Infusion Japan” ("i2.JP"; Website: ), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii). i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government. Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods. By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP. View source version on businesswire.com: Contacts Lightnix Inc. Akihiro ISUMI, General Manager +81-48-951-3637 info@lightnix.jp Source: Lightnix Inc. View this news release online at:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

AstraZeneca KK